CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

DISEASE CHARACTERISTICS:

* Histologically confirmed advanced solid tumor
* Refractory disease

  * Patients must have been offered and refused OR received and failed prior treatment with all standard or approved therapies for the malignancy
* Measurable or evaluable disease as confirmed by radiographic or clinical evidence
* No curative therapy available

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 3 months
* ANC \> 1,500/mm³
* Platelet count \> 75,000/mm³
* Hemoglobin ≥ 9.0 g/dL
* Creatinine ≤ 2.0 mg/dL
* AST and ALT \< 3 times upper limit of normal
* Not pregnant
* No nursing during and for ≥ 28 days after completion of study treatment
* Two negative pregnancy tests required
* Fertile women must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study treatment
* Men must use a latex condom during sexual contact with fertile females during and for ≥ 28 days after completion of study treatment, even if a prior successful vasectomy was performed
* Stable neurological exam
* No serious medical condition or psychiatric illness that would preclude study participation
* No prior desquamating rash or allergic reaction ≥ grade 2 while taking thalidomide, lenalidomide, or structurally related compounds
* No peripheral neuropathy ≥ grade 2
* No active infection
* No uncontrolled hyper- or hypocalcemia, glycosemia, or thyroidism

PRIOR CONCURRENT THERAPY:

* No prior CC-4047
* More than 28 days since prior cytotoxic chemotherapy (42 days for nitrosoureas)
* At least 14 days since prior therapeutic radiotherapy
* More than 14 days since prior thalidomide, lenalidomide, or structurally related compounds
* More than 14 days since prior biological response modifier therapy
* Concurrent radiotherapy to treat pain associated with existing bone lesions during the extension phase of the study allowed provided \< 10% of bone marrow is irradiated
* Concurrent systemic steroids for control of CNS primary tumor and/or metastases symptoms allowed provided dose is stable or decreasing AND patient is also taking low-dose aspirin and/or other platelet-active, anti-thrombotic medication during and for 30 days after completion of study treatment
* No other concurrent chemotherapy or immunotherapy
* No other concurrent investigational agents
* No concurrent hematopoietic growth factors during the treatment phase of the study
* No other concurrent anticancer agents